NEW YORK ( TheStreet) -- Myriad Genetics (Nasdaq: MYGN) hit a new 52-week high Friday as it is currently trading at $25.92, above its previous 52-week high of $25.89 with 869,319 shares traded as of 1:30 p.m. ET. Average volume has been 731,200 shares over the past 30 days. Myriad has a market cap of $1.98 billion and is part of the services sector and diversified services industry. Shares are up 13.5% year to date as of the close of trading on Thursday. Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of novel predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States. The company has a P/E ratio of 19.5, above the average diversified services industry P/E ratio of 19.1 and above the S&P 500 P/E ratio of 17.7.
- Sign up for TheStreet's FREE Dividend and Income Investor Newsletter